KR101816193B1 - Composition for inhibiting a cancer metastasis comprising an extract or fraction of herb medicine - Google Patents

Abstract

The present invention relates to a composition for suppressing cancer metastasis. By containing an extract obtained by extracting a mixture composed of Artemisiae Iwayomogii Herba, elecampane, poncirus, licorice, Salvia miltiorrhiza, Amomi Fructus, Polyporus Sclerotium, Poria Sclerotium, Atractylodis Rhizoma, Atractylodes macrocephala Koidzumi, Raphani Semen, Pelodiscis Carapax, and Alismatis Rhizoma, or a fraction as an active ingredient, it is possible to suppress metastasis of cancer to hepatic tissues. In addition, the composition is not toxic, and thus can be taken as foods.

Description

[0001] The present invention relates to a composition for inhibiting cancer metastasis comprising 13 kinds of herbal medicine extracts or fractions,

The present invention relates to a composition for inhibiting metastasis of cancer to liver tissue by containing extracts or fractions of 13 kinds of herbal medicines mixture as an active ingredient.

In Korea, the incidence and the spread of cancer among the causes of death are now 1-2, and in Korea, 79611 (28.6%) of the total deaths of 267,692 people died from cancer in 2014 150.9 per 100,000 people). Also, the mortality rate due to cancer is gradually increasing every year. In addition, in the United States, 584,881 people died of cancer in 2013, accounting for 22.4% (Centers for Disease Control and Prevention), and 90% of all cancer deaths were reported to be metastatic.

As a result, studies on the mechanism of invasion and metastasis of cancer cells and methods for inhibiting them have been actively conducted. The metastatic process of cancer cells is as follows. First, metastatic cancer cells are separated from the primary tumor and invade into the supporting structure such as epilepsy and basement membrane of the normal tissue, attach to the capillary wall of the other target tissue, decompose the extracellular matrix and basement membrane, The blood flow to the blood vessels and the new tissue is accompanied by angiogenesis and secondary tumor formation.

Thus, the metastatic process is composed of major steps such as migration, adhesion, and invasion. Cancer metastasis can be inhibited if either of them is blocked.

Most anticancer drugs have been developed for the purpose of suppressing the death or growth of cancer cells or cancer tissues. However, these drugs can not fundamentally remove the cancer, and it will be impossible to completely remove the cancer cells by the existing anticancer strategy in the future. do.

Therefore, "anti-metastatic drug", which inhibits metastasis, the most important event of cancer, has started to attract attention as a new cancer treatment target. Such "anti-metastatic drug" is not effective against cancer death or growth inhibition, It is a very important strategy for the management of cancer.

Korean Patent No. 1174074 Korean Patent No. 1284279

It is an object of the present invention to provide a pharmaceutical composition for inhibiting metastasis of cancer to liver tissue by containing extracts or fractions of 13 kinds of herbal medicines mixture as an active ingredient.

Another object of the present invention is to provide a food composition containing 13 kinds of extracts or fractions of a mixture of herbal medicines as an active ingredient, thereby preventing or improving the transfer of cancer to liver tissue.

In order to accomplish the above object, the pharmaceutical composition for suppressing cancer metastasis according to the present invention comprises an extract or a fraction obtained by extracting a mixture of Korean ginseng, Korean ginseng, ginseng, licorice, Danshen, As an active ingredient.

1: 1-3: 0.5-2: 2-6: 3-7: 0.2-7: 1, wherein the herbal composition is selected from the group consisting of Korean herbs, Korean herbaceous plants, 1: 1-4: 2-7: 0.5-4: 6-10: 2-5: 3-6: 0.3-0.9.

Such extracts or fractions include, but are not limited to, scopoletin, liquiritin, naringin, esculetin, rosmarinic acid, salvianolic acid B, Poncirin, Glycyrrhizic acid, and tanshinone IIA (Tanshinone IIA).

The extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethyl acetate, acetone, hexane, dichloromethane or a mixed solvent thereof.

The fraction may be obtained by fractionating the extract with chloroform, ethyl acetate, n-butanol, hexane, water or a mixture thereof.

The pharmaceutical composition for inhibiting cancer metastasis can inhibit metastasis of cancer to liver tissue.

In order to achieve the above and other objects, the present invention provides a food composition for preventing or ameliorating cancer metastasis, which comprises at least one selected from the group consisting of Korean herbs, Korean herbaceous plants, Or an extract or fraction obtained by extracting the mixture as an active ingredient.

The composition containing the extract and the fraction of the herbal medicine mixture of the present invention has an activity of inhibiting the transfer of cancer to liver tissue and thus can be usefully used as a composition for preventing and / or treating cancer and / or cancer metastasis.

In addition, the present invention can be used for a long term for suppressing cancer metastasis since it contains no harmful effect including a mixture of natural medicines as an active ingredient.

FIGS. 1A and 1B are graphs showing HPLC analysis of an extract of a mixture of medicinal herbs prepared according to Example 1, and FIG. 1C is a graph showing the contents of index components detected in FIGS. 1A and 1B.
2 is a graph showing the number of metastatic cancer cells clustered in hepatic tissue of a group 3 mouse injected with colon cancer cells.
FIG. 3 is a graph showing the weight of hepatic tissue isolated from three groups of mice injected with colon cancer cells.

The present invention relates to a composition for inhibiting metastasis of cancer to liver tissue by containing extracts or fractions of 13 kinds of herbal medicines mixture as an active ingredient.

The cancer is not particularly limited, but may be gastric cancer, colon cancer or rectal cancer.

Hereinafter, the present invention will be described in detail.

The composition for inhibiting metastasis of cancer to liver tissue of the present invention is effective as an extract or fraction obtained by extracting a mixture of Korean ginseng, Korean ginseng, ginseng, licorice, ginseng, cod, ginseng, gyeongryeong, .

The above-mentioned Artemisia iwayomogi Kitamura, Atractylodes chinensis Koidzumi, Polyporus umbellatus Fries and Alisma orientalis (Sam. Juzepczuk) are herb medicine used for gastrointestinal diseases, Which can help strengthen the stomach and help with edema and fluid metabolism.

In addition, atractylodes macrocephala Koidz, Poria cocos Wolf and licorice (Glycyrrhiza uralensis Fisch), respectively, facilitate the function of the digestive organs related to the dryness of the kidney, The state has been used as a medicinal herb that plays a role.

In addition, Poncirus trifoliate Rafin and Aucklandia lappa Decne are herb medicine which is known to communicate the aura of the human body from ancient times and helps the excretory function.

In addition, Raphanus sativus Linne and Amomum xanthioides Wallich are representative diad isoindolines, which promote the excretion of bile and help digestion function.

In addition, the Salvia miltiorrhiza Bunge and Trilynx sinensis Wiegmann smoothly circulate blood based on the action associated with the active blood vessels in Oriental medicine.

The above-mentioned 13 kinds of medicinal herb mixtures were classified into 1: 1-3: 0.5-2: 2-6: 3-7 (Korean cabbage, Korean cabbage, Korean cabbage, Korean cabbage, Korean cabbage, Korean cabbage, : 0.2-1: 1-4: 2-7: 0.5-4: 6-10: 2-5: 3-6: 0.3-0.9, preferably 1: 1-2: 1-2: 3- 4: 4-6: 0.5-0.9: 2-4: 3-5: 0.5-2: 7-9: 3-4: 4-5: 0.5-0.8.

When the above-mentioned 13 kinds of herbal medicines are mixed at a weight ratio deviating from the above-mentioned contents, the effect may be lowered and toxicity may be caused.

The herbal medicines mixture is mixed with an extraction solvent at a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, and extracted at 80 to 120 ° C to prepare an extract. When the weight ratio of the medicinal herb mixture to the extraction solvent is out of the above range, the effective ingredient of the medicinal herb mixture may be extracted in a small amount. If the extraction temperature is lower than the lower limit, the active ingredient of the herbal medicine mixture may not be extracted. If the extraction temperature is higher than the upper limit, the effective ingredient of the herbal medicine mixture may be extracted in a small amount.

As the extraction solvent for extracting the herbal composition mixture, water, a lower alcohol having 1 to 4 carbon atoms, ethyl acetate, acetone, hexane, dichloromethane or a mixed solvent thereof may be used, Preferably, it is extracted with water. The mixed solvent may be an aqueous solution of methanol, ethanol, butanol or propanol in an amount of 20 to 80% by volume.

The fraction of the herb mixture is mixed with the extract of the herbal mixture at a concentration of 5 to 30 times (w / w), preferably 8 to 20 times (w / w), followed by a conventional fractionation using a solvent To give a fraction. Examples of the solvent include chloroform, ethyl acetate, n-butanol, hexane, water, and mixtures thereof.

The extracts or fractions extracted from 13 kinds of herbal medicines include scopoletin, liquiritin, Naringin, esculetin, rosmarinic acid, salvianone B ( salvianolic acid B, poncirin, glycyrrhizic acid and tanshinone IIA to inhibit metastasis of cancer to liver tissue.

The term " extract " or " fraction " used herein to refer to the mixture of herbal medicines includes not only extracts or fractions obtained by treating the extraction solvent, but also extracts or fractions of the herbal medicines mixture. For example, the extract or fraction of the herbal mixture may be prepared in powder form by further processes such as vacuum distillation and lyophilization or spray drying.

In addition, the extract or fraction of the mixture of herbal medicines of the present invention has a meaning including a work of a mixture of medicinal herbicides formulated so as to be able to administer a mixture of medicinal herbicides to animals, for example, a mixture of medicinal herbicides. Although the present invention has been carried out with the extract or fraction of the herbal mixture, it is expected that those skilled in the art can achieve the desired effect in the same manner as the herbal mixture.

As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of the herbal mixture extract or fraction. For example, the extract or fraction of the herbal mixture is used at a concentration of 10 to 1500 mg / kg, preferably 50 to 500 mg / kg. Since the extracts or fractions of the herbal mixture are natural products, there is no adverse effect on the human body. Therefore, the quantitative upper limit of the herbal mixture extract or fractions contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.

The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a flavoring agent.

The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.

The pharmaceutical form of the pharmaceutical composition may be granules, powders, tablets, external preparation for skin, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules (oral preparations), the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the pharmaceutical composition of the present invention can be administered by intravenous infusion, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, vaginal administration, Administration.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, , A skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.

The pharmaceutical composition of the present invention can be prepared in a unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The present invention also provides a food composition for prevention or improvement of cancer metastasis which comprises an extract of a herbal medicine mixture or a fraction thereof as an active ingredient.

The food composition according to the present invention can be formulated in the same manner as the above-mentioned pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .

The food composition of the present invention may contain, as an active ingredient, an extract or a fraction of a mixture of herbal medicines, as well as a component that is ordinarily added during the manufacture of a food. Examples thereof include proteins, carbohydrates, fats, nutrients, . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, and various plant extracts in addition to the extract or fraction of the mixture of the herbal medicines of the present invention .

The present invention provides a health functional food comprising a food composition for preventing or ameliorating cancer metastasis comprising the herbal composition mixture extract or fraction as an active ingredient. The health functional food refers to a food prepared by adding an extract or fraction of a mixture of herbal medicines to food materials such as beverages, tea, spices, gums and confectionery, or by encapsulation, powdering, or suspension, However, unlike general medicine, there is an advantage that there is no side effect that may occur when a food is used as a raw material for a long period of taking the medicine. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the herbal medicine mixture extract added in such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not deteriorate the original taste of the food, 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In the case of a health functional food in the form of pills, granules, tablets or capsules, it is usually added in an amount of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

The present invention also provides the use of the herbal medicine mixture extract or fraction for the production of a medicament for suppressing cancer metastasis or food. As described above, the herbal composition mixture extract or the fraction can be used for suppressing cancer metastasis.

The present invention also provides a method of inhibiting metastasis comprising administering to a mammal an effective amount of an extract or fraction of a mixture of herbal medicines.

The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.

As used herein, the term "effective amount" refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. The effective amount and the administration frequency for the active ingredient of the present invention can be changed according to the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the prevention, treatment or improvement method of the present invention, in the case of an adult, it is preferable to administer the extract at a dose of 0.001 g / kg to 10 g / kg once to several times a day.

In the treatment method of the present invention, the composition comprising the extract or fraction of the herbal mixture as an active ingredient can be administered orally, rectally, vaginally, intravenously, intraarterially, intraperitoneally, intramuscularly, intrasternally, transdermally, topically, In a conventional manner.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.

EXAMPLES Example 1. A herbal medicine water extract

Herbal medicine mixture

1.2: 1.8: 3.3: 4.5: 0.7: 2.5: 3.5: 1.4: 8.0: 3.5: 4.0: 0.7 By weight to prepare a medicinal herb mixture.

extract

The medicinal herb mixture was thoroughly washed, pulverized and powdered. The mixture of the medicinal herb mixture powder and distilled water was mixed at a weight ratio of 1:10, heated at 100 ° C for 150 minutes, and then the solid matter was removed to obtain an extract.

<Test Example>

Test Example 1. Measurement of the index component

In order to measure the surface component, the extract was concentrated, and the extract was separated by filtration and centrifugation. The supernatant was lyophilized to obtain an extract extract, and the indicator components were measured.

FIGS. 1A and 1B are graphs showing HPLC analysis of an extract of a mixture of medicinal herbs prepared according to Example 1, and FIG. 1C is a graph showing the contents of index components detected in FIGS. 1A and 1B.

As shown in Figs. 1A to 1C, a mixture of scopoletin, liquiritin, naringin, esculetin, rosmarinic acid, 9 compounds were detected in the extracts of salicylic acid B, salvianolic acid B, poncirin, glycyrrhizic acid and tanshinone IIA.

Among these compounds, Esculetin was confirmed to be a substance contained in the above extract although it was very small.

Test Example 2. Evaluation of efficacy on animal models

Mouse preparation

Experimental animals were purchased from BioLink (Chungbuk, Korea) with 24 male C57BL / 6N mice (weight 13-25 g) 10 weeks old. The mice were housed for 7 days at room temperature (23 ± 1 ℃) and 60% humidity under 12 hours of light cycle (light cycle from 7: 00-19: 00). All test materials used in this experiment were orally administered at the same time every day.

Three groups of mice -

A: Six 50 mg / kg administered groups of 50 mg / kg of the extract of Example 1 orally for 7 days; CGX50

B: 6 mice of the 100 mg / kg group administered orally for 7 days with 100 mg / kg of the extract of Example 1; CGX100

C: 6 control mice administered with distilled water only for 7 days; control

Mouse sacrifice

For the transfer to the liver tissue via the nasal cavity, the mice of the three groups orally administered for 7 days were administered with mouse-derived colorectal cancer cells, MC38 cells, at a concentration of 2 × 10 ⁵ cells / mL, After colonization period of colon cancer cells, autopsy was performed after sacrifice after 18 hours of fasting.

At the time of the autopsy, the hepatic tissue was separated to confirm the cluster of metastatic cancer, and the liver tissue was weighed and the blood of the mouse was obtained from the abdominal vein.

evaluation

2 is a graph showing the number of metastatic cancer cells clustered in hepatic tissue of a group 3 mouse injected with colon cancer cells.

As shown in FIG. 2, the number of metastatic cancer cells in the CGX50 group and the CGX100 group was significantly smaller than that in the control group. In particular, the number of metastatic cancer cells was smaller in the CGX100 group than in the CGX50 group.

FIG. 3 is a graph showing the weight of hepatic tissue isolated from three groups of mice injected with colon cancer cells.

As shown in FIG. 3, the weight of liver tissue of the CGX50 group and the CGX100 group was decreased compared to the control group. In particular, the weight of the liver tissue was further decreased in the CGX100 group than in the CGX50 group.

Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation example  One. Sanje  Produce

500 mg of the extract powder obtained in Example 1

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

300 mg of the extract powder obtained in Example 1

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation example  3. Preparation of capsules

200 mg of the extract powder obtained in Example 1

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

600 mg of the extract powder obtained in Example 1

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO _{4 ,} 12H ₂ O 26 mg

It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.

Formulation example  5. Liquid  Produce

4 g of the extract powder obtained in Example 1

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 g with purified water, To prepare a liquid agent.

Formulation example  6. Preparation of granules

1,000 mg of the extract powder obtained in Example 1

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 [mu] g vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the above-mentioned vitamins and minerals is comparatively comparatively mixed with the granules according to the preferred embodiment. However, the blending ratio may be arbitrarily changed, and the above components are mixed according to the ordinary granule preparation method, Can be prepared and used in the manufacture of a health functional food composition according to a conventional method.

Formulation example  7. Manufacture of functional beverages

 1,000 mg of the extract powder obtained in Example 1

Citric acid 1,000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to the flask to obtain a total of 900 mL

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the compounding ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (7)

1: 1-3: 0.5-2: 2-6: 3-7: 0.2-1: 1 - 1: 1 - 1: Wherein the extract or fraction obtained by extracting the mixed mixture at a weight ratio of 4: 2-7: 0.5-4: 6-10: 2-5: 3-6: 0.3-0.9 is contained as an active ingredient. A pharmaceutical composition for suppressing cancer metastasis. delete 3. The method of claim 1, wherein the extract or fraction is selected from the group consisting of scopoletin, liquiritin, Naringin, esculetin, rosmarinic acid, salvianolic acid, acid B, poncirin, glycyrrhizic acid, and tanshinone IIA (IIA) are contained in the pharmaceutical composition for suppressing cancer metastasis. The pharmaceutical composition according to claim 1, wherein the extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethyl acetate, acetone, hexane, dichloromethane or a mixed solvent thereof. The pharmaceutical composition for suppressing cancer metastasis according to claim 1, wherein the fraction is obtained by fractionating the extract with chloroform, ethyl acetate, n-butanol, hexane, water or a mixture thereof. delete 1: 1-3: 0.5-2: 2-6: 3-7: 0.2-1: 1 - 1: 1 - 1: Wherein the extract or fraction obtained by extracting the mixed mixture at a weight ratio of 4: 2-7: 0.5-4: 6-10: 2-5: 3-6: 0.3-0.9 is contained as an active ingredient. A food composition for preventing or ameliorating cancer.

Images